Literature DB >> 17664233

Monoclonal gammopathy in systemic lupus erythematosus.

Y M Ali1, M B Urowitz, D Ibanez, D D Gladman.   

Abstract

We studied the prevalence, type and associated features of monoclonal gammopathy in patients with systemic lupus erythematosus (SLE). Patients included in the University of Toronto Lupus Database with an abnormal band on serum electropheresis were identified. Monoclonal gammopathy patients were matched with two controls each from the same database by age at SLE diagnosis, sex and disease duration. Of 1083 patients followed at the Lupus Clinic 59 (5.4%) were identified with monoclonal gammopathy. The gammopathies included 32 with IgG, 14 IgM and 12 IgA, one undefined. Nine (15.3%) malignancies were detected in monoclonal gammopathy and 12 (10.1%) in the controls during the entire course of their disease (P = 0.13). None had multiple myeloma. There was no difference between patients with monoclonal gammopathy and their controls with respect to disease activity, damage, or dose of steroids. The mean ESR and gammaglobulin levels in the monoclonal gammopathy patients were higher than the controls at last visit. We conclude that monoclonal gammopathy is more frequent in SLE patients than in the general population and has a benign course in patients with SLE. There were no differences in disease manifestations, treatment approaches, or malignancies between SLE patients with and those without monoclonal gammopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17664233     DOI: 10.1177/0961203307079045

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  7 in total

1.  Rheumatologic diseases impact the risk of progression of MGUS to overt multiple myeloma.

Authors:  Normann Steiner; Georg Göbel; Daniela Michaeler; Anna-Luise Platz; Wolfgang Prokop; Anna Maria Wolf; Dominik Wolf; Christina Duftner; Eberhard Gunsilius
Journal:  Blood Adv       Date:  2021-03-23

Review 2.  Early onset multiple myeloma in a patient with systemic lupus erythematosus: a case report and literature review.

Authors:  Jin Woo Choi; Seung Woo Han; Ki Tae Kwon; Gun Woo Kim
Journal:  Clin Rheumatol       Date:  2010-03-07       Impact factor: 2.980

3.  Monoclonal gammopathy in rheumatic diseases.

Authors:  Yue Yang; Long Chen; Yuan Jia; Yang Liu; Lei Wen; Yaoxian Liang; Yuan An; Shi Chen; Yin Su; Zhanguo Li
Journal:  Clin Rheumatol       Date:  2018-03-13       Impact factor: 2.980

4.  Malignancy in systemic lupus erythematosus: what have we learned?

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2009-08       Impact factor: 4.098

5.  A Case Report of Premalignant Plasma Cell Dyscrasia-Induced Renal Failure in a 31-Year-Old Female.

Authors:  Ayrton Bangolo; Mahabuba Akhter; Amer Jarri; Manpreet Kaur; Ali Atoot; Parul Jandir; Mahmood Ibrahim; Lochana Manandhar; Adam Atoot
Journal:  Case Rep Hematol       Date:  2022-06-07

Review 6.  Malignancies in systemic lupus erythematosus.

Authors:  Emese Kiss; Laszlo Kovacs; Peter Szodoray
Journal:  Autoimmun Rev       Date:  2009-07-27       Impact factor: 9.754

Review 7.  [Monoclonal gammopathy of undetermined significance and multiple myeloma].

Authors:  M Schmalzing; H-P Tony; S Knop
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.